OPKO Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OPKO Health, Inc. on December 29, 2011, regarding events occurring on that date. The report details the completion of an asset acquisition involving an Israeli pharmaceutical entity.
Key Financial Metrics and Transaction Details
The filing reports the acquisition of FineTech Pharmaceutical Ltd. for a total consideration of $27.5 million. The payment structure consisted of:
- Cash Payment: $10.0 million paid at closing.
- Stock Payment: $17.5 million paid in OPKO Health common stock.
In connection with the transaction, the Company issued 2,995,868 shares of common stock to the seller. Additionally, 619,835 shares were deposited into an escrow account to secure indemnification obligations. The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the Company or the acquired entity within this document.
Material Changes
The primary material change is the expansion of the Company's portfolio through the acquisition of FineTech Pharmaceutical Ltd. This transaction resulted in an immediate cash outflow of $10 million and an increase in outstanding common shares by approximately 3.6 million (issued plus escrowed).
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management outlook, or specific risk factors related to the acquisition beyond standard regulatory disclosures. The Company intends to file required financial statements of the acquired business and pro forma financial information via an amendment to this report within 71 calendar days. The stock issuance was made in reliance on an exemption from registration requirements under Section 4(2) of the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the total consideration of $27.5 million and the split between cash ($10M) and stock ($17.5M).
- Confirm the issuance of 2,995,868 shares and the escrow of 619,835 shares.
- Monitor the upcoming amendment to this 8-K for the required financial statements of FineTech Pharmaceutical Ltd. and pro forma financial information.
- Review the press release filed as Exhibit 99.1 for additional strategic context regarding the acquisition.